![{{press_release.company_name}} header image](https://res.cloudinary.com/dmgi9movl/image/upload/dpr_auto,w_auto/v1689836769/press_release/assets/header_images/SYNDEO_1500_x_700_mwllvm.png)
FOR IMMEDIATE RELEASE
20 July 2023 – SYNDEO Medical, a leading provider of fully integrated custom procedural solution products, has entered into a multi-year global distribution agreement with Clozex Medical, Inc., a leading US-based company specializing in advanced wound closure solutions. This strategic collaboration marks a significant milestone for both companies and aims to enhance patient care and revolutionize wound closure solutions across the globe.
Under this agreement, SYNDEO Medical has acquired the rights to distribute Clozex Medical's FDA-approved advanced wound closure products in the Middle East and Africa, with optional global rights that may be exercised by SYNDEO Medical. This partnership enables SYNDEO Medical to expand its product portfolio, complementing its existing line of minimally invasive interventional and surgical solutions. By integrating Clozex Medical's state-of-the-art wound closure technologies, SYNDEO Medical reinforces its commitment to providing healthcare providers with innovative medical devices and solutions.
Justin J. Lampropoulos, CEO of SYNDEO Medical, expressed his enthusiasm about the collaboration: "We are thrilled to announce this multi-year global distribution agreement with Clozex Medical. This partnership allows us to offer a comprehensive suite of advanced wound closure solutions alongside our rapidly growing procedural solutions portfolio. At SYNDEO Medical, we are committed to elevating patient care, delivering value, and empowering outcomes. Clozex Medical's cutting-edge wound closure products align perfectly with our mission, and together, we aim to make a meaningful impact on patient outcomes globally."
Clozex Medical's Global Vice President of Sales, Matthew Papagno, also conveyed his excitement about the partnership: "The collaboration with SYNDEO Medical is a momentous occasion for Clozex Medical. SYNDEO Medical's extensive reach and commitment to advancing patient care make them an ideal partner to introduce our advanced wound closure solutions to a wider global audience. By combining our strengths, we will contribute to raising the standards of wound closure techniques and provide healthcare providers with the latest advancements in this critical field."
For more information about SYNDEO Medical or Clozex Medical, Inc., please visit syndeomedical.be or clozex.com, respectively.
SYNDEO Medical is engaged in the design and development of fully integrated custom procedural solution products. Founded in 2022 by Justin J. Lampropoulos and headquartered in Belgium, SYNDEO Medical is dedicated to pushing the boundaries of healthcare innovation. Specializing in minimally invasive interventional and surgical products, SYNDEO Medical serves healthcare providers worldwide through a network of distribution partners and sales representatives. The company is committed to positively impacting lives through elevating patient experience, delivering meaningful value, and empowering outcomes.
The announcement of the multi-year global distribution agreement between SYNDEO Medical and Clozex Medical, Inc.® is for informational purposes only and should not be construed as an offer to sell or distribute any products in any particular jurisdiction. The availability of products mentioned in this press release may vary and is subject to regulatory approval in each respective jurisdiction.
Furthermore, all trademarks mentioned in this press release are the property of their respective owners. Any references to specific trademarks or registered trademarks are purely for descriptive purposes and do not imply any affiliation or endorsement between the parties involved.
Healthcare providers and individuals interested in obtaining products from SYNDEO Medical or Clozex Medical, Inc.® should verify the product's availability and regulatory status in their respective jurisdictions before making any purchasing decisions.
For more detailed information regarding product availability, regulatory approval status, and trademark ownership, please contact the relevant companies directly through their official websites or authorized representatives.